Rajasthan's Drug Control Department has ordered an immediate recall of a specific batch of Dinoprostone Gel manufactured by Cotec Healthcare. The medication, used for labor induction, failed government quality tests at a laboratory in Jaipur. Hospitals across the state have been instructed to stop using the product and return remaining stock to ensure patient safety.
The Rajasthan Drug Control Department has launched a state-wide recall of a specific batch of Dinoprostone Gel, a critical medication used to induce labor and soften the cervix in pregnant women. This regulatory action follows laboratory results from the state’s Drug Testing Laboratory in Jaipur, which found that batch number H-084 did not meet the required safety and quality standards. The sample was originally collected from the New Medical College Hospital (NMCH) store in Kota on May 17.
Impact on Supply and Distribution
Authorities have identified approximately 1,117 units of the affected batch currently in the state's inventory. To prioritize patient safety, the department has issued a directive to all government medical facilities to immediately stop using the product and initiate the return of the stock to the manufacturer, Cotec Healthcare Private Limited, based in Roorkee, Uttarakhand. As this medication is used in sensitive maternity care, the failure of the drug to meet quality standards poses a significant risk to hospital procurement processes and patient welfare.
Context of Regulatory Scrutiny
This incident has renewed discussions regarding the quality control mechanisms for medical supplies in public health institutions. The recall follows an earlier, high-profile case involving a different maternity drug, Oxytocin, which was also found to be substandard after being administered at the same Medical College Hospital in Kota. In that instance, investigations suggested that the injections lacked the necessary active ingredients. That prior event led to intervention by the National Human Rights Commission (NHRC) following a complaint by Jan Swasthya Abhiyan India. The organization’s complaint highlighted broader concerns about the oversight of pharmaceutical supply chains, demanding accountability for manufacturers and stricter drug monitoring to prevent the administration of ineffective or harmful medicines.
Monitoring Next Steps
For investors and stakeholders in the healthcare sector, the primary monitorable remains the company’s ability to ensure product quality and the potential for stricter regulatory oversight on government tenders. The investigation into why this specific batch failed to meet standards is ongoing. The final impact on the company will depend on the findings of the drug control authorities and whether any further punitive measures or contract restrictions are imposed by state health departments.